LLAI vs. PRM, GDR, ABDX, GENI, VRCI, POLX, IMM, RUA, GENF, and CNSL
Should you be buying LungLife AI stock or one of its competitors? The main competitors of LungLife AI include Proteome Sciences (PRM), genedrive (GDR), Abingdon Health (ABDX), GENinCode (GENI), Verici Dx (VRCI), Polarean Imaging (POLX), ImmuPharma (IMM), RUA Life Sciences (RUA), Genflow Biosciences (GENF), and Cambridge Nutritional Sciences (CNSL). These companies are all part of the "medical" sector.
LungLife AI (LON:LLAI) and Proteome Sciences (LON:PRM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, dividends, analyst recommendations, valuation, community ranking, earnings and media sentiment.
42.2% of LungLife AI shares are held by institutional investors. Comparatively, 23.0% of Proteome Sciences shares are held by institutional investors. 48.7% of LungLife AI shares are held by insiders. Comparatively, 19.5% of Proteome Sciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
LungLife AI has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500. Comparatively, Proteome Sciences has a beta of -0.02, meaning that its stock price is 102% less volatile than the S&P 500.
In the previous week, Proteome Sciences had 1 more articles in the media than LungLife AI. MarketBeat recorded 1 mentions for Proteome Sciences and 0 mentions for LungLife AI. Proteome Sciences' average media sentiment score of 0.21 beat LungLife AI's score of 0.00 indicating that Proteome Sciences is being referred to more favorably in the news media.
LungLife AI has a net margin of 0.00% compared to Proteome Sciences' net margin of -48.59%. Proteome Sciences' return on equity of 0.00% beat LungLife AI's return on equity.
Proteome Sciences has higher revenue and earnings than LungLife AI. Proteome Sciences is trading at a lower price-to-earnings ratio than LungLife AI, indicating that it is currently the more affordable of the two stocks.
Proteome Sciences received 162 more outperform votes than LungLife AI when rated by MarketBeat users.
Summary
Proteome Sciences beats LungLife AI on 9 of the 14 factors compared between the two stocks.
Get LungLife AI News Delivered to You Automatically
Sign up to receive the latest news and ratings for LLAI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LLAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
LungLife AI Competitors List
Related Companies and Tools
